SPYRE THERAPEUTICS INC (SYRE) Fundamental Analysis & Valuation

NASDAQ:SYRE • US00773J2024

Current stock price

44.07 USD
+4.18 (+10.48%)
At close:
43.15 USD
-0.92 (-2.09%)
Pre-Market:

This SYRE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. SYRE Profitability Analysis

1.1 Basic Checks

  • SYRE had negative earnings in the past year.
  • SYRE had a negative operating cash flow in the past year.
  • SYRE had negative earnings in each of the past 5 years.
  • SYRE had a negative operating cash flow in each of the past 5 years.
SYRE Yearly Net Income VS EBIT VS OCF VS FCFSYRE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M

1.2 Ratios

  • SYRE's Return On Assets of -29.49% is fine compared to the rest of the industry. SYRE outperforms 66.99% of its industry peers.
  • With a decent Return On Equity value of -32.69%, SYRE is doing good in the industry, outperforming 72.78% of the companies in the same industry.
Industry RankSector Rank
ROA -29.49%
ROE -32.69%
ROIC N/A
ROA(3y)-51.08%
ROA(5y)-66.2%
ROE(3y)-62.67%
ROE(5y)-86.62%
ROIC(3y)N/A
ROIC(5y)N/A
SYRE Yearly ROA, ROE, ROICSYRE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SYRE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SYRE Yearly Profit, Operating, Gross MarginsSYRE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. SYRE Health Analysis

2.1 Basic Checks

  • SYRE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, SYRE has more shares outstanding
  • SYRE has more shares outstanding than it did 5 years ago.
  • SYRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SYRE Yearly Shares OutstandingSYRE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
SYRE Yearly Total Debt VS Total AssetsSYRE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • SYRE has an Altman-Z score of 38.62. This indicates that SYRE is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 38.62, SYRE belongs to the best of the industry, outperforming 94.40% of the companies in the same industry.
  • SYRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 38.62
ROIC/WACCN/A
WACC8.92%
SYRE Yearly LT Debt VS Equity VS FCFSYRE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 10.90 indicates that SYRE has no problem at all paying its short term obligations.
  • SYRE has a better Current ratio (10.90) than 84.17% of its industry peers.
  • SYRE has a Quick Ratio of 10.90. This indicates that SYRE is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 10.90, SYRE belongs to the top of the industry, outperforming 84.17% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.9
Quick Ratio 10.9
SYRE Yearly Current Assets VS Current LiabilitesSYRE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. SYRE Growth Analysis

3.1 Past

  • SYRE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 47.52%, which is quite impressive.
EPS 1Y (TTM)47.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -10.10% on average over the next years. This is quite bad
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-34.9%
EPS Next 2Y-20.48%
EPS Next 3Y-15.87%
EPS Next 5Y-10.1%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SYRE Yearly Revenue VS EstimatesSYRE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2021 2022 2023 2024 2029 2030 2031 2032 2033 500M 1B 1.5B
SYRE Yearly EPS VS EstimatesSYRE Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -50 -100 -150 -200

More info and screens

Find the best growth stocksShow best growing peers

0

4. SYRE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SYRE. In the last year negative earnings were reported.
  • Also next year SYRE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SYRE Price Earnings VS Forward Price EarningsSYRE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SYRE Per share dataSYRE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • A cheap valuation may be justified as SYRE's earnings are expected to decrease with -15.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.48%
EPS Next 3Y-15.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SYRE Dividend Analysis

5.1 Amount

  • SYRE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SYRE Fundamentals: All Metrics, Ratios and Statistics

SPYRE THERAPEUTICS INC

NASDAQ:SYRE (3/16/2026, 8:00:00 PM)

Premarket: 43.15 -0.92 (-2.09%)

44.07

+4.18 (+10.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19
Earnings (Next)05-06
Inst Owners100.75%
Inst Owner ChangeN/A
Ins Owners6.66%
Ins Owner Change-12.41%
Market Cap3.46B
Revenue(TTM)N/A
Net Income(TTM)-148.79M
Analysts89.52
Price Target59.74 (35.56%)
Short Float %14.25%
Short Ratio14.36
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)40.06%
Min EPS beat(2)-0.17%
Max EPS beat(2)80.3%
EPS beat(4)3
Avg EPS beat(4)32.57%
Min EPS beat(4)-0.17%
Max EPS beat(4)80.3%
EPS beat(8)4
Avg EPS beat(8)-40.91%
EPS beat(12)5
Avg EPS beat(12)-176.02%
EPS beat(16)7
Avg EPS beat(16)-130.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.8%
PT rev (3m)12.44%
EPS NQ rev (1m)-16.73%
EPS NQ rev (3m)0.89%
EPS NY rev (1m)-8.54%
EPS NY rev (3m)-12.87%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.61
P/tB 7.61
EV/EBITDA N/A
EPS(TTM)-2.22
EYN/A
EPS(NY)-2.99
Fwd EYN/A
FCF(TTM)-2.06
FCFYN/A
OCF(TTM)-2.06
OCFYN/A
SpS0
BVpS5.79
TBVpS5.79
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -29.49%
ROE -32.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-51.08%
ROA(5y)-66.2%
ROE(3y)-62.67%
ROE(5y)-86.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.9
Quick Ratio 10.9
Altman-Z 38.62
F-Score4
WACC8.92%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.58%
EPS Next Y-34.9%
EPS Next 2Y-20.48%
EPS Next 3Y-15.87%
EPS Next 5Y-10.1%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.72%
EBIT Next 3Y-10.01%
EBIT Next 5Y5.34%
FCF growth 1Y-7.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-7.04%
OCF growth 3YN/A
OCF growth 5YN/A

SPYRE THERAPEUTICS INC / SYRE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SPYRE THERAPEUTICS INC (SYRE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SYRE.


What is the valuation status of SPYRE THERAPEUTICS INC (SYRE) stock?

ChartMill assigns a valuation rating of 0 / 10 to SPYRE THERAPEUTICS INC (SYRE). This can be considered as Overvalued.


Can you provide the profitability details for SPYRE THERAPEUTICS INC?

SPYRE THERAPEUTICS INC (SYRE) has a profitability rating of 1 / 10.